Health ❯ Healthcare ❯ Clinical Trials ❯ Patient Outcomes

Quality of Life

Sacituzumab Govitecan Gains First-Line Ground in TNBC, Falls Short in Early HR+/HER2− Use

SABCS presentations underscore subtype‑specific use requiring careful treatment sequencing.

TORPEdO Phase III Finds No One-Year Advantage for Proton Therapy Over IMRT in Oropharyngeal Cancer